CRISPR Therapeutics AG (NASDAQ:CRSP) tinted gains of +1.1% (+0.28 points) to US$25.77. The volume of 0.29 Million shares climbed down over an trading activity of 421.83 Million shares. EPS ratio determined by looking at last 12 month figures is -0.32. Over the same time span, the stock marked US$28.5 as its best level and the lowest price reached was US$11.63. The corporation has a market cap of US$942.67 Million.
CRISPR Therapeutics AG (NASDAQ:CRSP)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -24.9 percent while most common profitability ratio return on investment (ROI) was -24.5 percent. The company’s institutional ownership is monitored at 42.9 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 3 think it is Hold. Recently, analysts have updated the overall rating to 2.29. 3 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) is worth US$75.9 Million and has recently fallen -2.96% to US$3.28. The latest exchange of 0.08 Million shares is below its average trading activity of 45.62 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$15 while the mean 12-month price target for the shares is US$15.5.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.77, and a price to sales ratio of 39.95. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 0%. With an institutional ownership near 0.6%, it carries an earnings per share ratio of -1.12.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 1.5.